Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
S

ASH 2019 Updates on Large Cell Lymphoma: Use of ClonoSEQ in Diagnosis, PET-Directed Therapy in Limited-Stage DLBCL, Burkitt Lymphoma Treatment Options & MATRIX-RICE followed by ASCT for CNS Lymphoma

By Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient FEATURING Sunita D. Nasta
By Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient FEATURING Sunita D. Nasta
0 views
February 25, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

34:36
MyCancerHaven

Frontline DLBCL Treatment Approaches

Feat. R. Vij, H. Cherng
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg